spacer
home > ict > autumn 2018 > streamlining start-ups
PUBLICATIONS
International Clinical Trials

Streamlining Start-Ups

New life sciences industry research reveals significant momentum towards streamlining clinical systems and processes over the past year. More than 300 clinical operations professionals from around the globe were surveyed in an annual unified clinical operations survey to track the industry’s progress in improving clinical operations. Nearly all clinical leaders (99%) recognise the need to unify their clinical operating environments, and most (87%) have plans in place to get there.

Better Visibility and Faster Trial Execution

The widespread move to unify clinical environments is being driven by application and process silos that have resulted from the steady adoption of function-specific clinical technologies over the past decade. Stand-alone eClinical applications, including electronic data capture, electronic trial master files (eTMFs), randomisation and trial supply management, and clinical trial management systems (CTMSs) are now the norm. Newer, purpose-built applications, such as study start-up, are gaining traction (1).

Faced with a landscape of disparate systems and processes, over three quarters (77%) of those surveyed find better visibility across their clinical trial processes a top driver for unifying clinical applications. Other primary drivers include faster study execution (67%), improved study quality (62%), and increased productivity (51%).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rik Van Mol is Vice President of R&D Strategy at Veeva Systems, responsible for the Veeva Vault R&D suite of applications in Europe. Rik has nearly 20 years of experience in business/IT consulting and has regulated content management in the life sciences sector. His experience has been built on assisting clients through complex transformational programmes across the life sciences value chain, including clinical, regulatory, and manufacturing/supply chain areas for some of the world’s largest companies.
spacer
Rik Van Mol
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

TAGRISSOTM (osimertinib) DEMONSTRATED UNPRECEDENTED DISEASE-FREE SURVIVAL IN THE ADJUVANT TREATMENT OF STAGE IB-IIIA COMPLETELY RESECTED PATIENTS WITH EGFR MUTATION

Detailed results from the Phase III ADAURA trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
More info >>

White Papers

pAVEway™ expression system for the efficient expression of therapeutic proteins

Fujifilm Diosynth Biotechnologies

One of the major bottlenecks in the production of biopharmaceuticals is the efficient expression of therapeutic proteins in microbial or mammalian cells. The Escherichia coli pAVEway™ expression system described here has been developed to ensure high product titres and efficient scale up to GMP manufacture, whilst minimising many common issues seen in other expression systems, such as ‘leaky’ expression (expression of recombinant protein in the absence of inducer).
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement